Tenax Therapeutics Inc (TENX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $73.77M
Last updated: Nov 17, 2026 at 11:05 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 17.1% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 35.4, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about TENX
GNG News
All TENX news- TENXEvercore ISI Group downgrades Tenax Therapeutics (TENX) to In-Line
Historical
- TENXWilliam Blair cuts Tenax Therapeutics (TENX) rating to Market Perform
UpdatedHistorical
- TENXChardan Capital cuts Tenax Therapeutics (TENX) rating to Neutral
UpdatedHistorical
- TENXTenax Therapeutics (TENX) receives Neutral downgrade from Guggenheim
UpdatedHistorical
News
TENX Valuation
Tenax Therapeutics (TENX) trades at 0.3x forward earnings.
- Forward P/E
- 0.3x
- P/FCF
- -1.6x
- P/B
- 0.7x
TENX Profitability: Margins, ROIC and FCF
Tenax Therapeutics (TENX) has an operating margin of 0.0% and a net margin of 0.0%.
- Operating margin
- 0.0%
- Net margin
- 0.0%
- ROE
- -64.2%
- FCF yield
- -62.4%
Tenax Therapeutics Competitors
The companies most similar to Tenax Therapeutics (TENX) include Tenaya Therapeutics, Tonix Pharmaceuticals Holding and NRX Pharmaceuticals.
Sector: Healthcare
Companies most similar to Tenax TherapeuticsTENX Analyst Ratings
Tenax Therapeutics (TENX) has a Buy consensus from 10 analysts: 6 Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 10
- Strong Buy
- 1
- Buy
- 5
- Hold
- 4
- Sell
- 0
- Strong Sell
- 0
TENX Bull Case vs Bear Case
Bull case
- TENX beat EPS estimates in 100.0% of its last 8 reported quarters.
- 60.0% of TENX's analyst ratings are Buy or Strong Buy.
TENX Earnings: Beat Rate and Next Report
Tenax Therapeutics (TENX) beat the EPS estimate in 8 of the last 8 quarters (100.0%). Its next report is expected on Mar 8, 2027.
- Beat rate
- 8 of 8 quarters (100.0%)
- Average surprise
- 29.2%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$0.36
TENX Earnings Date
TENX reports Mar 8, 2027. The date is estimated.
TENX ETF Holders
GNG tracks 4 ETFs that hold TENX. The largest weights:
- Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
- Dimensional U.S. Core Equity 2 ETF (DFAC), <0.01% of the fund
- Fidelity Enhanced Small Cap Core ETF (FESM), <0.01% of the fund
- Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
Updated Nov 7, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About TENX
When does TENX report earnings?
Tenax Therapeutics Inc (TENX) is expected to report earnings on Mar 8, 2027.
Does TENX pay dividends?
Tenax Therapeutics Inc (TENX) does not currently pay a regular dividend.
What is TENX's market cap?
Tenax Therapeutics Inc (TENX) has a market capitalization of $73.77M with a current stock price of $1.48.
TENX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.